8-K: Exicure Faces Nasdaq Delisting After Failing to Meet Filing Deadlines

Exicure, Inc. has received a delisting notice from Nasdaq due to its failure to file its 2023 Form 10-K and Q1 2024 Form 10-Q, and not holding its 2023 annual meeting.

Summary

• Exicure, Inc. received a delisting notice from Nasdaq because it did not file its Form 10-K for the year ended December 31, 2023, by the extended deadline of May 20, 2024.
• The company also failed to file its Form 10-Q for the first quarter of 2024 and has not held its 2023 Annual Meeting of Stockholders, which are additional reasons for delisting.
• Trading of Exicure's common stock is set to be suspended on May 30, 2024, unless the company appeals the decision by May 28, 2024.
• Exicure intends to appeal the delisting determination and submit a plan to regain compliance with Nasdaq listing requirements.
• The company is working to complete the Form 10-K and Q1 Form 10-Q and plans to hold a combined 2023 and 2024 Annual Meeting of Stockholders as soon as possible.
• There is no guarantee that Exicure will regain compliance or be successful in its appeal.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the delisting notice, indicating significant issues with compliance and financial reporting. The company's future is uncertain.

Positives

• Exicure intends to appeal the delisting decision by the May 28, 2024 deadline.
• The company plans to submit a plan to regain compliance with Nasdaq listing requirements.
• Management is working to complete the overdue Form 10-K and Q1 Form 10-Q filings.
• Exicure is planning to hold a combined 2023 and 2024 Annual Meeting of Stockholders.

Negatives

• Exicure received a delisting notice from Nasdaq due to the failure to file its 2023 Form 10-K by the extended deadline.
• The company also failed to file its Q1 2024 Form 10-Q and has not held its 2023 Annual Meeting of Stockholders.
• Trading of Exicure's stock is set to be suspended on May 30, 2024, if an appeal is not filed.
• There is no assurance that the company will regain compliance with Nasdaq listing requirements or be successful in its appeal.

Risks

• There is a risk of unanticipated delays in filing the Form 10-K and Q1 Form 10-Q.
• The work required to complete the filings may be more extensive than anticipated.
• The company may not respond adequately to further inquiries from Nasdaq.
• Nasdaq may not accept the company's plan to regain compliance, leading to delisting.
• The company may not be granted an extended stay pending the hearing.

Future Outlook

The company is focused on completing its overdue filings and appealing the delisting notice, but there is no guarantee of success. Exicure is also exploring strategic alternatives to maximize stockholder value.

Management Comments

• The Company's management is working diligently to complete the Form 10-K and Q1 Form 10-Q and intends to file them as soon as practicable.
• The Company's management is also working diligently to hold a combined 2023 and 2024 Annual Meeting of Stockholders as soon as practicable.

Industry Context

This announcement highlights the importance of regulatory compliance for publicly traded companies. Failure to meet filing deadlines can lead to significant consequences, including delisting from major stock exchanges. This is a common issue for companies that are experiencing financial or operational difficulties.

Comparison to Industry Standards

• Many biotech companies face challenges in meeting regulatory deadlines, but delisting is a severe outcome.
• Companies like Sorrento Therapeutics and Cassava Sciences have faced similar scrutiny regarding financial reporting and compliance, but not all have faced delisting.
• The failure to file financial reports on time is a significant breach of corporate governance standards and is not typical for companies listed on major exchanges like Nasdaq.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and relationships with suppliers and partners may be negatively affected.

Next Steps

• Exicure intends to file an appeal to Nasdaq's Hearings Panel by May 28, 2024.
• The company will submit a plan to regain compliance with all applicable listing requirements.
• Exicure will seek an extended stay of the trading suspension pending the hearing.
• The company will complete and file the Form 10-K and Q1 Form 10-Q as soon as practicable.
• Exicure will hold a combined 2023 and 2024 Annual Meeting of Stockholders.

Key Dates

Keywords

delisting, Nasdaq, Form 10-K, Form 10-Q, compliance, appeal, annual meeting, filing, suspension, stockholders